PRISM is an interdisciplinary laboratory integrating i.e. Biologists, molecular biologists, Biochemists, Chemists, and Physicians issued from University of Lille, Cancer Center Oscar Lambret (COL) and the University Hospital Center (CHU Lille).
The Technological Innovations axis arose from the MALDI Imaging Team (MIT) created in 2002 by Prof. I. Fournier devoted to MALDI MS Imaging (MALDI MSI). MIT was one of pioneer in Worldwide of MALDI MSI and is now one of the world leaders in spatially-resolved tissue micro-proteomic coupled to High Resolution MALDI MSI for clinical applications targeting precision medicine.
Since 2004, MIT researches were focused on i) technological developments and ii) clinical applications transversally to the second axis of the unit. MITtargets since its beginnings on the development of MALDI MSI first with improvements in i) tissue preparation for both Fresh frozen and Formalin–Fixed Paraffin-Embedded (FFPE) samples and ii) biomolecules identification with preserved spatial localization. This was pursed through the development of novel MALDI matrices (ionic matrices), of matrix deposition methods (spraying devices, automatic spotting with piezoelectric head), on-tissue micro-digestion and on-tissue tryptic peptide derivatization, unlocking FFPE tissue, bioinformatics (novel imaging software, MITICS, Principal-Component Analysis-Symbolic Discriminant Analysis method (PCA-SDA)), novel pre-spotted MALDI plates with ionic matrices, as well as targeted MALDI-MSI based on Tag-Mass.
MIT now has emphasis on four main projects for MALDI MSI improvement, and these projects consist of 1) on-tissue micro-proteomics for high throughput protein identification based on state-of-the-art proteomics technologies, 2) on-tissue protein quantification, 3) on-tissue protein structure analyses, and 4) correlations between transciptome and proteome. All of these developments are included in two major work packages so-called Ex vivo (For biomarkers Hunting) including QUEST-MSI and Ghost and In vivo (For personalized Diagnosis and prognosis) including SPIDERMASS and Snoop-I.
The Therapeutic Innovations axis is organized in 2 integrated work packages which are translational from basic science to clinics.
WP1 is focused on Neuroimmunology and WP2 on Oncoimmunology but the heart of these 2 WPs is the macrophages/microglia cell response modulation. WP1 (Regenesis) includes two tasks: so-called Neurobridge and Exodus, while WP2 (Caron: Caron on Oncology) is based on one integrated project divided into 3 tasks: Resistance, Recurrence and Risk.
Resistance, Recurrence, Risk